Microbiology

Shop By

Items 1-50 of 129

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Pyrimethamine(RP4753) is a medication used for protozoal infections; interferes with tetrahydrofolic acid synthesis from folic acid by inhibiting the enzyme dihydrofolate reductase (DHFR).
  2. Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections. Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci.
  3. CCR5 antagonist

    Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).
  4. CCR2 antagonist

    MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.
  5. CCR2 Antagonist

    INCB8761(PF-4136309) is a potent, selective, and orally bioavailable CCR2 antagonist.
  6. NS3 protease inhibitor

    Asunaprevir is an inhibitor of the viral enzyme serine protease NS3.
  7. β-lactamase inhibitor

    Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.
  8. Avermectin B1a is an antiparasitic agent that paralyzes nematodes without causing hypercontraction or flaccid paralysis.
  9. Polymerase inhibitor

    Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).
  10. NNRT inhibitor

    Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.
  11. Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics.
  12. CCR2 antagonist

    INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
  13. HCV Nucleoside Inhibitor

    PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor.
  14. NNRT inhibitor

    Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.
  15. Radezolid is a novel oxazolidinone antibiotic agent.
  16. PC-PLC inhibitor

    SPK-601 (LMV-601) is an inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC). SPK-601 also can be used as an antimicrobial agent.
  17. NS5B polymerase inhibitor

    Tegobuvir (GS-9190 is a non-nucleoside NS5B polymerase inhibitor.
  18. RSV fusion inhibitor

    TMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.
  19. BM212 is inhibitory to drug-resistant mycobacteria and also exerted bactericidal activity against intracellular bacilli residing in the U937 human histiocytic lymphoma cell line.
  20. CCR4 antagonist

    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96??0.11.
  21. HCV NS5B polymerase inhibitor

    VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
  22. Ceftaroline fosamil is a cephalosporin antibacterial.
  23. NNRT inhibitor

    MK-1439 is a non-nucleoside reverse transcriptase inhibitor
  24. PKG inhibitor

    MBP146-78 is a potent and selective inhibitor of cGMP dependent protein kinases.
  25. HIV protease inhibitor

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
  26. SK channel inhibitor

    ICA (N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine) is a SK channel inhibitor that has antileishmanial activity with an IC50 of 2.1 ?M.
  27. Anti-Wolbachia agent

    AWZ1066S is a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis, with an EC50 of 2.5 nM in cell assay.
  28. CCR 2 antagonist

    Teijin compound 1 is a specific CCR 2 antagonist with IC50s of 24 and 180 nM in chemotaxis and binding assay, respectively.
  29. HCV NS3 inhibitor

    GS-9451 is a potent macrocyclic HCV NS3 PI that achieved a median maximal change in HCV RNA of 3.6 log10 IU/mL (range, -4.7 log10 to -3.1 log10 IU/mL) following 3-day monotherapy in treatment-nave patients with HCV genotype 1 infection during phase I.
  30. Ganciclovir Mono-O-acetate is a ganciclovir derivative.
  31. DL-cycloserine is an antibacterial (tuberculostatic).
  32. IMPDH inhibitor

    AVN-944 (also known as VX-944) serves as an effective oral inhibitor, specifically targeting and inhibiting IMPDH (inosine monophosphate dehydrogenase). This enzyme plays a crucial role as a rate-limiting factor in the synthesis of guanine nucleotides from scratch. Additionally, AVN-944 acts against the synthesis of RNA in arenaviruses, effectively preventing arenavirus infections. Demonstrating a wide spectrum of anti-cancer properties, AVN-944 is utilized in research related to multiple myeloma (MM) and acute myeloid leukemia (AML).

  33. Quinupristin is a semi-synthetic analogue of virginiamycin B (ostreogyrcin B, pristinamycin IA, Streptogramin B) formed by a Mannich condensation and elimination to generate an exocyclic methylene alpha to the ketone of the 4-piperidinone.
  34. NS1 antagonist

    ML303 is a pyrazolopyridine influenza virus nonstructural protein 1 (NS1) antagonist (IC90 = 155 nM), with an EC50 of 0.7 μM for Influenza A virus H1N1.
  35. Prodigiosin (Prodigiosine) is a secondary metabolite of Symbiotic bacteria, with anti-fungal and anti-cancer activity.
  36. CCR5 antagonist

    TAK-779 is a novel, potent and selective small-molecule antagonists of CCR5 with the IC50 value of 1.4nM in binding assay.
  37. Rolitetracycline is a tetracycline antibiotic.
  38. Erythromycin Cyclocarbonate, derivative of Erythromycin, inhibits protein synthesis of bacteria by binding to the 50S ribosome.
  39. NF-κB inhibitor

    SC75741 is a potent NF-kB inhibitor with EC50 of 200 nM.
  40. Amadacycline is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.
  41. Amadacycline methanesulfonate is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.
  42. HIV-1 attachment inhibitor

    BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.
  43. HIV-1 attachment inhibitor

    BMS-663068 tris is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.
  44. I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis.
  45. HCV replication inhibitor

    RO-9187 is a potent inhibitor of HCV virus replication in the replicon system (IC(50) = 171 +/- 12 nM; CC(50) >1 mM).
  46. CCR2 antagonist.

    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 uM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).
  47. CCR5 antagonist

    Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1.
  48. HCV Polymerase Inhibitor

    VCH-759 is a non-nucleoside inhibitor of HCV RNA-dependent polymerase with sub-micromolar IC50 values versus genotype 1a/1b replicons.
  49. Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
  50. Calcineurin/PP2B inhibitor

    Ascomycin is an ethyl analog of tacrolimus (FK506) with strong immunosuppressant properties. It has been researched for the treatment of autoimmune diseases and skin diseases, and to prevent rejection after an organ transplant.

Items 1-50 of 129

Page
per page
Set Descending Direction